Skip to content
Precision for Medicine

Announcing the Institute@Precision, a Collaborative Forum for Biopharma Innovation.

iStock-1500823492 (1) iStock-1500823492 (1)

Streamline Your Study Start Up with Precision

Kickstart your clinical trials with efficiency and expertise.
In today’s fast-paced clinical trial environment, initiating your study effectively is more critical than ever. Precision's approach to Study Start Up combines technological innovation, regulatory insight, and global expertise to optimize every phase of trial initiation, ensuring your study begins with the momentum needed to succeed.
iStock-1332002332 (1) (1)

Accelerating your clinical trial start up

Successful clinical trials begin with a well-executed study start up. By focusing on strategic site selection and swift regulatory submissions,  Precision’s global study start up team helps set the foundation for timely and successful trial outcomes. Our team delivers site activation with precision by leveraging locally dedicated staff and through close partnership with our Regulatory Affairs department. Through this synergy, we streamline submissions across North America, Europe, and Asia Pacific. Every study presents its own unique challenges therefore it's critical to work with seasoned staff dedicated to guiding effective study start up.
5 Average years of start up experience
45 countries supported by Precision’s Start Up team

Our Proven Pathway to Study Start Up Success

Precision's study start up services are built on a foundation of detailed planning and proactive strategy. From identifying the most suitable sites worldwide to navigating the complexities of local and global regulations, our team ensures your study is initiated without delay. With a focus on cross-functional collaboration, accountability, and proactive risk management, we partner with you to accelerate patients' access to life-changing therapies.
The Precision path

Expert perspectives from Precision

Gain new insights and strategies from our experts at the forefront of clinical and translational research.

Read: Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity

Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=159488778872, hs_child_table_id=0, hs_updated_at=1744653337128, hs_published_at=1762900001827, description=Visionary leader with decades of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Darren%20Davis.webp',altText='Darren Davis',fileId=165891429693}, linkedin=https://www.linkedin.com/in/drdarrendavis, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Davis, PhD, hs_initial_published_at=1762810487559, hs_created_at=1709645745103, hs_is_edited=false, hs_deleted_at=0, name=Darren, job=Senior Vice President, Translational Sciences, slug=darren-davis, email=, hs_updated_by_user_id=78347666}, second={hs_id=167888548278, hs_child_table_id=0, hs_updated_at=1722451546286, hs_published_at=1762900001827, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716194887110, hs_created_by_user_id=2737751, hs_created_at=1716194842710, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job=Chief Scientific Officer, slug=deborah-phippard-translational-sciences, email=, hs_updated_by_user_id=78347666}, third={hs_id=159488778883, hs_child_table_id=0, hs_updated_at=1762803857448, hs_published_at=1762900001827, description=Jie Yang, PhD is a Scientific Liaison for Precision for Medicine. An Immunologist by training with extensive industry expertise in designing translational assays for biomarker-guided clinical trials. Conducted postdoctoral research on immuno-oncology at MD Anderson Cancer Center. Led biomarker assay development and collaborated on the implementation of new technologies for pre-clinical and clinical studies conducted by pharmaceutical and biotech companies for drug development., avatar=Image{width=885,height=886,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Jie-Yang.png',altText='Jie-Yang',fileId=167372215352}, linkedin=https://www.linkedin.com/in/jie-yang-0528221b, hs_name=, hs_path=, lastname=Yang, PhD, hs_initial_published_at=1762810487559, hs_created_at=1709645745114, hs_is_edited=false, hs_deleted_at=0, name=Jie, job=, slug=jie-yang, email=, hs_updated_by_user_id=78347666}})
  • Darren D. avatar Deborah P. avatar Jie Y. avatar
  • Darren D.

    Deborah P.

    Jie Y.

Discover
Read: Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket

Biomarkers

Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=199138167916, hs_child_table_id=0, hs_updated_at=1762375981786, hs_published_at=1762900001827, avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Paul%20Steven.png',altText='Paul Steven',fileId=199144298570}, lastname=Steven, hs_initial_published_at=1762375986271, hs_created_by_user_id=26433386, hs_created_at=1762375951865, hs_is_edited=false, hs_deleted_at=0, name=Paul, job=Principal Biostatistician, slug=paul-steven, hs_updated_by_user_id=78347666}, second={}, third={}})
  • Paul Steven avatar

    Paul Steven

Discover
Read: Investor Relations, Clinical Operations, and the Future of Biotech Financing Investor Relations, Clinical Operations, and the Future of Biotech Financing

Clinical Trials - Translational Research - Early Phase Research

Investor Relations, Clinical Operations, and the Future of Biotech Financing

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548862, hs_child_table_id=0, hs_updated_at=1716454315513, hs_published_at=1762900001827, description=Teresa is a respected business development strategist, building successful clinical programs for clients in Massachusetts. She is an innovator of fresh approaches to biomarker planning, translational solutions, and clinical study design. Her experience spans the execution of Phase 1-4 clinical trials, specialty lab services, companion and in vitro diagnostic strategies, and biomarker data management., avatar=Image{width=700,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Teresa-Pokladowski-300x300.png',altText='Teresa-Pokladowski-300x300',fileId=168135942975}, linkedin=https://www.linkedin.com/in/teresapokladowski/, lastname=Pokladowski, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713362443509, hs_is_edited=false, hs_deleted_at=0, name=Teresa, job=Regional Vice President, Clinical Business Solutions, North America, slug=teresa-pokladowski, hs_updated_by_user_id=78347666}, second={hs_id=197608580658, hs_child_table_id=0, hs_updated_at=1760465121471, hs_published_at=1762900001827, description=Hannah Dereseiwicz is a strategic force in investor relations, helping biotech innovators translate complex science into compelling narratives that drive engagement and growth. With a track record spanning commercial launches, M&A activity, and high-stakes communications, she brings clarity, confidence, and momentum to every stage of a company’s journey. Hannah’s approach is defined by the three A’s—ambitious, approachable, and authentic—making her a trusted partner for teams looking to elevate their story and connect with the audiences that matter most., avatar=Image{width=636,height=476,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hannah%20Deresiewicz.webp',altText='Hannah Deresiewicz',fileId=197608718507}, lastname=Deresiewicz, hs_initial_published_at=1760465283803, hs_created_by_user_id=26433386, hs_created_at=1760464991513, hs_is_edited=false, hs_deleted_at=0, name=Hannah, job=Executive Vice President, Managing Director Precision AQ – Investor Relations & External Communications, slug=hannah-deresiewicz, hs_updated_by_user_id=78347666}, third={}})
  • Teresa P. avatar

    Teresa P.

  • Hannah D. avatar

    Hannah D.

Discover
  • Discover Early Phase Excellence
    82 (1)

    Early Phase Excellence

    Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy

    Explore
  • Discover Late Phase Success
    late-phase

    Late Phase Success

    Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.

    Explore

Deep experience with debilitating disease and unique modalities

Like you, we understand that there’s a patient throughout the development pathway. Supporting our partners to bring innovative treatments to patients is our purpose. Leverage our experience in these therapeutic areas.

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore